Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile Relapse in acute myeloid leukemia is common and is thought to arise from minimal residual disease (MRD) cells surviving chemotherapy. 1 Survival of MRD cells has been attributed to drug resistance mechanisms. Defects in apoptosis pathways are probably contributing significantly to resistance to a variety of chemotherapeutic agents. Despite an emerging knowledge of the regulatory mechanisms of apoptosis, Bcl-2 still stands at the top of the list of parameters that contribute to chemotherapeutic resistance. In AML, it has been shown that Bcl-2 is of independent prognostic significance. High Bcl-2 predicts failure to achieve complete remission 2 and shorter overall survival. 3 In this study the expression profile of Bcl-2 and Bcl-2 related proteins in MRD cells was determined to examine whether chemotherapy-induced upregulation of an apoptosis-resistant protein profile or selection of subpopulations with a high Regulation of IAP and caspase ubiquitination by integrins. (a) Nalm-6 cells were stimulated for 2 days with Fn (F2) or PLL (P2) in the absence of serum. IAP2, XIAP or caspase 7 were immunoprecipitated and analyzed by Western blot using anti-Ubiquitin and anti-IAP2, XIAP or caspase 7 antibodies. TCL ¼ total cell lysate. An immunoprecipitation with an irrelevant antibody is also shown for XIAP (IpC vs IpX). For ubiquitination experiments, Fn/PLL ratios were quantified by densitometry analyses and indicated at the bottom of each panel (F/P: x%). (b) Cells were first stimulated with Fn or PLL for 18 h before adding MG132 (1 mM) or not (Ctrl) for 8 h. The samples were analyzed by Western blot using anti-Ubiquitin and anti-XIAP or caspase 7 antibodies. These experiments are representative of three independent experiments.
anti-apoptosis protein profile occurs during chemotherapeutic treatment.
In all, 61 AML patients were enrolled in this study after informed consent. Fresh bone marrow (BM) aspirates were obtained at diagnosis (n ¼ 61), after first cycle of induction chemotherapy (n ¼ 22), second cycle of induction (n ¼ 15) and after postinduction cycle (n ¼ 10) of chemotherapy, at follow-up (n ¼ 13), and at relapse (n ¼ 9). The median age was 54 years, 29 male and 32 female subjects distributed over RAEB-t (5 Â ), M0 (5 Â ), M1 (7 Â ), M2 (14 Â ), M3 (2 Â ), M4 (12 Â ), M5 (10 Â ), M6 (3 Â ), unknown (3 Â ) according to the FAB classification. In toal, 11 normal BM (nBM) from healthy donors were included.
To enable the study of apoptosis-related protein expression in MRD cells, we relied upon an intracellular flow cytometry method. 4, 5 Briefly, this method consists of two parts; firstly, patient-specific leukemia-associated phenotypes (LAPs) are determined at diagnosis followed by an intracellular procedure to detect the Bcl-2-related proteins in these cells. The LAP can then be used to detect MRD cells in follow-up BM samples. (Figure 1g) show decreases in expression. Overall, it can be concluded that MRD cells have significantly lower Bcl-2 levels after chemotherapeutic treatment (cycle 1: P ¼ 0.01, cycle 2: P ¼ 0.0008, cycle 3: P ¼ 0.04) and at follow-up (FU1: P ¼ 0.01 and FU2: P ¼ 0.01) than at diagnosis.
In contrast, Bcl-2 levels from refractory patients showed no change after first (P ¼ 0.64) or second cycle (P ¼ 0.79) (Figure 1h ).
Despite the fact that the MRD cells in CR were apoptosissensitive as compared to diagnosis, they were able to survive chemotherapy resulting in some cases in relapse. Bcl-2 expression at relapse had again increased to the level comparable to diagnosis (no difference with diagnosis; P ¼ 0.69) after the described decrease in an MRD situation.
Two other anti-apoptosis proteins Bcl-x L and Mcl-1 and the proapoptotic protein Bax were also studied (Table 1) . In summary, although less prominent compared to Bcl-2, in responding patients Bcl-x L and Mcl-1 significantly decreased from the second cycle onwards (Table 1a) , while no change was observed in refractory patients (Table 1b) . Relapse samples had similar protein levels as at diagnosis. On the other hand, Bax showed an increased expression compared to diagnosis, reaching significance after the first cycle of chemotherapy in responding patients. This shows that the prominent results found for the anti-apoptosis proteins are not the results of aspecific treatment-related cellular changes.
Overall, our data show that MRD blasts do not have a more apoptosis resistant profile. Instead, when a complete remission is achieved, in the majority of patients MRD cells are apoptosis sensitive compared to diagnosis and remain apoptosis sensitive throughout the remission period. Only when patients do not reach a CR or when patients relapse, the leukemic blasts retain their diagnosis apoptosis protein profile. These unexpected results clearly show that neither chemotherapy-induced upregulation of an apoptosis-resistant protein profile nor selection of subpopulations with a high anti-apoptosis protein profile occurs. 556a, 2184) that AML tumor supernatants can inhibit apoptosis of malignant hematopoietic cells. Combined with our observation this might indicate that AML cells at diagnosis, in follow-up situations of refractory patients and at relapse produce apoptosis-regulating factors that affect neighbouring cells, while in a CR BM due to the very limited number of AML cells, production is ineffective. Such cells might however be affected by the BM stroma: Konopleva et al 7 found that a stromal cell line was able to increase Bcl-2 expression in blasts of 5/11 AML patients. It may then be hypothesized that intact BM stroma from AML patients may induce upregulation of anti-apoptosis profiles in intact stroma, while such may be impossible in damaged stroma, the latter in fact resembling the actual situation in remission BM after chemotherapy. Leukemic blasts at all measurements were identified by a low CD45 expression in combination with a LAP marker expression.
